SVB Wealth LLC Makes New Investment in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

SVB Wealth LLC purchased a new position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 18,981 shares of the company’s stock, valued at approximately $300,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its position in shares of Dr. Reddy’s Laboratories by 43.2% in the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after buying an additional 137 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Dr. Reddy’s Laboratories in the third quarter worth about $60,000. Van ECK Associates Corp lifted its position in shares of Dr. Reddy’s Laboratories by 64.3% in the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock worth $64,000 after buying an additional 322 shares during the last quarter. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after buying an additional 1,820 shares during the last quarter. Finally, Glenmede Trust Co. NA acquired a new stake in shares of Dr. Reddy’s Laboratories in the third quarter worth about $207,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

NYSE RDY opened at $12.92 on Thursday. Dr. Reddy’s Laboratories Limited has a twelve month low of $12.62 and a twelve month high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a market capitalization of $10.78 billion, a PE ratio of 20.57 and a beta of 0.50. The stock has a 50-day simple moving average of $14.34 and a 200 day simple moving average of $15.00.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Research analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Barclays cut their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.